Literature DB >> 30480487

Autologous Blood Patch Injection versus Hydrogel Plug in CT-guided Lung Biopsy: A Prospective Randomized Trial.

Majid Maybody1, Nadim Muallem1, Karen T Brown1, Chaya S Moskowitz1, Meier Hsu1, Christina L Zenobi1, Marwah Jihad1, George I Getrajdman1, Constantinos T Sofocleous1, Joseph P Erinjeri1, Anne M Covey1, Lynn A Brody1, Hooman Yarmohammadi1, Amy R Deipolyi1, Yolanda Bryce1, William Alago1, Robert H Siegelbaum1, Jeremy C Durack1, Adrian J Gonzalez-Aguirre1, Etay Ziv1, F Edward Boas1, Stephen B Solomon1.   

Abstract

Purpose To compare the effect of autologous blood patch injection (ABPI) with that of a hydrogel plug on the rate of pneumothorax at CT-guided percutaneous lung biopsy. Materials and Methods In this prospective randomized controlled trial ( https://ClinicalTrials.gov , NCT02224924), a noninferiority design was used for ABPI, with a 10% noninferiority margin when compared with the hydrogel plug, with the primary outcome of pneumothorax rate within 2 hours of biopsy. A type I error rate of 0.05 and 90% power were specified with a target study population of 552 participants (276 in each arm). From October 2014 to February 2017, all potential study participants referred for CT-guided lung biopsy (n = 2052) were assessed for enrollment. Results The data safety monitoring board recommended the trial be closed to accrual after an interim analysis met prespecified criteria for early stopping based on noninferiority. The final study group consisted of 453 participants who were randomly assigned to the ABPI (n = 226) or hydrogel plug (n = 227) arms. Of these, 407 underwent lung biopsy. Pneumothorax rates within 2 hours of biopsy were 21% (42 of 199) and 29% (60 of 208); chest tube rates were 9% (18 of 199) and 13% (27 of 208); and delayed pneumothorax rates within 2 weeks after biopsy were 1.4% (three of 199) and 1.5% (three of 208) in the ABPI and hydrogel plug arms, respectively. Conclusion Autologous blood patch injection is noninferior to a hydrogel plug regarding the rate of pneumothorax after CT-guided percutaneous lung biopsy. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30480487      PMCID: PMC6357949          DOI: 10.1148/radiol.2018181140

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Efficacy of Tract Embolization After Percutaneous Pulmonary Radiofrequency Ablation.

Authors:  Michael Dassa; Jean Izaaryene; Nassima Daidj; Gilles Piana
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-25       Impact factor: 2.740

2.  Hemoptysis associated with percutaneous transthoracic needle biopsy: Development of critical events checklist and procedure outcomes.

Authors:  Piera C Robson; David O'Connor; Perri Pardini; Terrah F Akard; Mary S Dietrich; Alan Kotin; Alexandra Solomon; Mohit Chawla; Matthew Kennedy; Stephen B Solomon
Journal:  J Radiol Nurs       Date:  2021-05-25

Review 3.  Interventional oncology at the time of COVID-19 pandemic: Problems and solutions.

Authors:  A Denys; B Guiu; P Chevallier; A Digklia; E de Kerviler; T de Baere
Journal:  Diagn Interv Imaging       Date:  2020-04-23       Impact factor: 4.026

4.  Costs of Biopsy and Complications in Patients with Lung Cancer.

Authors:  Yu-Wen Chiu; Yu-Hsiang Kao; Michael J Simoff; David E Ost; Oliver Wagner; James Lavin; Richard A Culbertson; Dean G Smith
Journal:  Clinicoecon Outcomes Res       Date:  2021-03-17

5.  Biopsy frequency and complications among lung cancer patients in the United States.

Authors:  Yichen Zhang; Lizheng Shi; Michael J Simoff; Oliver J Wagner; James Lavin
Journal:  Lung Cancer Manag       Date:  2020-08-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.